Savaria Stock Earnings Reports

Q1 2026 highlights: Savaria reported consolidated revenue of $235.5M (up ~7% YoY), adjusted EBITDA of $48.1M (20.4% margin, +190 bps YoY), net earnings of $22.7M (up 82% YoY) and EPS of $0.31. Growth was broad-based across segments and regions: Accessibility grew ~7.9% led by stronger European stairlift demand and Canada (including Western acquisition), while Patient Care grew ~3.8% (6.5% organic, FX headwinds from USD). Savaria One transformation remains active (about 200 initiatives in flight, ~40 implemented in Q1) and management attributes roughly $7M of Q1 EBITDA improvement to those initiatives. Operational positives include gross margin expansion (38.9% vs 37.8% prior year) from pricing, procurement and operating leverage, improved factory throughput (notably Beamsville beds), stronger direct stores, and successful integration/turnaround of Matot and in‑house electronics (Ultron) which mitigates supply-chain/chip risks. Balance sheet and capital allocation: net debt/EBITDA ~0.92x, $324M available liquidity, and M&A appetite for ~ $200M of small/mid acquisitions over five years. CapEx is guided slightly above historic 2–2.5% of sales (but below 3%) due to Greenville expansion; working capital days improved despite dollar increase. Near-term items to watch: continued Savaria One initiative realizations, European product rollouts (new straight stairlift, platform/VPL/Luma traction), Greenville manufacturing ramp, and FX/tariff sensitivity (management says finished goods are compliant and tariff exposure is limited). Management reiterates a mid/long‑term target of ~12% annual revenue growth to about $1.6B by 2030 while maintaining adjusted EBITDA margins >=20%.